UK Markets closed

Acurx Pharmaceuticals, Inc. (ACXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.4500-0.0700 (-1.55%)
As of 03:41PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 35.9200
52-week low 32.3300
50-day moving average 33.6088
200-day moving average 33.9255

Share statistics

Avg vol (3-month) 320.14k
Avg vol (10-day) 345.5k
Shares outstanding 510.22M
Implied shares outstanding 6N/A
Float 87.81M
% held by insiders 123.35%
% held by institutions 13.14%
Shares short (14 Jul 2022) 422.21k
Short ratio (14 Jul 2022) 41.89
Short % of float (14 Jul 2022) 40.28%
Short % of shares outstanding (14 Jul 2022) 40.22%
Shares short (prior month 14 Jun 2022) 456.45k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-122.43%
Return on equity (ttm)-211.90%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-13.94M
Diluted EPS (ttm)-1.4790
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)11.08M
Total cash per share (mrq)1.08
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)17.89
Book value per share (mrq)1.41

Cash flow statement

Operating cash flow (ttm)-6.34M
Levered free cash flow (ttm)-1.5M